Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2025-10-14 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
关于修订公司部分治理制度的公告
Governance Information Classification · 95% confidence The document is an announcement from the company's board regarding revisions to certain corporate governance policies, specifically the 'Accounting Firm Selection System.' It mentions that the revisions have been approved by the board and audit committee and that the revised policies will be disclosed on the stock exchange website. There is no detailed report or financial data included, only a governance-related announcement. The document is short (680 characters) and serves as a formal notice of governance changes, not the governance report itself. Therefore, it fits best under 'Governance Information' (CGR).
2025-10-14 Chinese
关于独立董事辞任暨补选独立董事并调整董事会专门委员会委员的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of an independent director and the election of a new independent director, along with adjustments to the board committees. It includes details about the director's resignation, the nomination and qualifications of the new director, and committee membership changes. There are no financial statements, earnings data, or regulatory filings related to financial performance. The content clearly pertains to changes in the company's board of directors and management structure. Therefore, this document fits the category of Board/Management Information (MANG). The document length is relatively short and focused on management changes, not a full report or announcement of a report publication.
2025-10-14 Chinese
关于变更公司2025年度财务报告及内部控制审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the change of the company's auditor for the 2025 fiscal year financial report and internal control audit. It details the new and former accounting firms, reasons for the change, communication with the previous auditor, and the approval process by the audit committee and board. It does not contain the actual financial report or audit results but is a formal announcement about the auditor change. The document length is 3222 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, it fits best under Audit Report / Information (AR) as it relates specifically to audit information and auditor changes, but since it is an announcement of auditor change rather than the audit report itself, it is more appropriate to classify as AR rather than 10-K or RPA. Confidence is high due to clear content focus on audit institution change and related details. FY 2025
2025-10-14 Chinese
第二届董事会提名委员会关于第二届董事会独立董事候选人任职资格的审查意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from the Nomination Committee of the Board of Directors regarding the qualification review of an independent director candidate. It discusses compliance with company law, regulations, and internal rules, and concludes with a nomination recommendation to the board. There is no financial data, no mention of financial results, no shareholder voting results, no legal proceedings, and no report publication. The content is about board/management information specifically related to director nomination and qualifications. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and focused on management nomination, not a report or announcement of a report.
2025-10-14 Chinese
第二届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of 海创药业股份有限公司. It details the meeting date, attendance, and specific board decisions such as amendments to governance policies, changes in audit firms, resignation and replacement of independent directors, and committee adjustments. The document also mentions that these resolutions require approval at an upcoming shareholders' meeting. There are no financial statements or detailed financial data presented, nor is this a transcript or presentation. The content focuses on board decisions and governance matters. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 2516 characters, which is relatively short and consistent with an announcement rather than a full report. Hence, the classification is MANG with high confidence.
2025-10-14 Chinese
中信证券股份有限公司关于海创药业股份有限公司首次公开发行部分限售股上市流通的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the listing and circulation of restricted shares from the initial public offering of Haichuang Pharmaceutical Co., Ltd. It references regulatory approvals, specific share quantities, lock-up commitments, and compliance with securities laws. The document is not an announcement of a report but a formal verification opinion related to share circulation and compliance. It does not contain financial statements or earnings data, nor is it a management or audit report. The content focuses on share listing and circulation verification, which aligns with a Capital/Financing Update (CAP) category, as it deals with share issuance and circulation matters post-IPO.
2025-09-26 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.